ReviewInflammopharmacology2026
Repurposing of doxycycline as a novel therapeutic avenue for management of parkinson's disease.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease subsequent to Alzheimers disease (AD). PD is characterized by progressive neurodegeneration of the dopaminergic neurons in the substantia nigra pars compacta (SNpc). Notably, the management of PD is chiefly symptomatic without modifying the underlying PD neuropathology. Moreover, prolonged use of anti-PD medications may be correlated with severe harmful effects such as dyskinesia and neuronal oxidative stress. Consequently, repurposing FDA-permitted therapies with antioxidants and anti-inflammatory capacities may prevent the progression of PD neuropathology. The antibiotic doxycycline has been shown to alleviate PD neuropathology by restraining the development of neurodegeneration, neuroinflammation, oxidative stress, and endoplasmic reticulum (ER) stress. However, the molecular mechanism of doxycycline in PD is not fully explained. Hence, this review purposes to examine the various effects of doxycycline regarding its potential molecular mechanism alongside the progression of PD.
Indexed as
Identifiers
41925933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.